From Lab to Life: Dr. Ingrid Swanson Pultz’s Revolutionary Journey in Protein Design
At the University of Washington in 2007, Dr. Ingrid Swanson Pultz found herself seeking a new direction in her scientific career. While her microbiology lab work was fulfilling, she yearned to create novel biological solutions. This desire led her to become a pioneer in protein design, a field that has revolutionized the development of therapeutics, vaccines, and biosensors.
Pultz’s journey began when she established the University of Washington’s first iGEM team, an international undergraduate competition focused on creating biological systems. This decision would prove transformative not only for her career but for the entire field of protein design.
A breakthrough came in 2011 when Pultz, alongside graduate student Justin Seigel, guided an undergraduate team in developing a solution for celiac disease. Working with Dr. David Baker, who would later win the 2024 Nobel Prize, they utilized the Rosetta software to design an enzyme specifically targeting gluten. The project, known as KumaMax, was groundbreaking – it needed to function precisely in the
challenging environment of the human stomach while exclusively breaking down gluten proteins.
Their success was remarkable, earning them the distinction of being the first American team to win the iGEM competition. Rather than letting the project end with the competition, Pultz recognized its potential and continued development as a postdoctoral researcher in Baker’s lab. She became the Institute for Protein Design’s first translational investigator, focusing on commercializing the
technology.
Laboratory tests demonstrated KumaMax’s effectiveness in reducing immunogenic gluten in various foods, from beer to hamburgers, under simulated gastric conditions. This success led Pultz and Seigel to establish PvP Biologics. Rather than pursuing traditional venture capital funding, they secured a strategic partnership with Takeda Pharmaceuticals, which later acquired the company for $330 million in 2020. Currently, KumaMax is progressing through phase two clinical trials.
Now serving as chief technology officer at Mopac, another Institute for Protein Design spinoff, Pultz continues to advance the field of protein design. She emphasizes the technology’s vast potential in addressing health and environmental challenges, particularly as artificial intelligence and machine learning have dramatically improved protein design capabilities in the decade since KumaMax’s development.
KumaMax holds special significance as the first practical application of Baker’s Nobel Prize-winning methodologies. Pultz believes this recognition will help bring protein design science into the
mainstream, highlighting its potential to impact people’s lives meaningfully.
Beyond her research, Pultz dedicates significant time to mentoring the next generation of biotechnology innovators. She serves as an advisor at the Institute for Protein Design and mentors at Creative
Destruction Lab, a University of Washington Foster School of Business program supporting computational health startups. This commitment to nurturing new talent has earned her recognition from industry veterans like Emer Dooley, who praises Pultz’s dedication to supporting others at all career stages.
Pultz’s work exemplifies how scientific innovation, combined with entrepreneurial drive, can transform laboratory discoveries into life-changing solutions. Her journey from creating a student competition team to developing groundbreaking protein designs demonstrates the power of pursuing novel approaches in biotechnology. Through her ongoing work in protein design and her commitment to mentoring others, Pultz continues to shape the future of therapeutic solutions while building a stronger biotechnology ecosystem in the Pacific Northwest.
